CA2503490A1 - Medical device surface coating comprising bioactive compound - Google Patents
Medical device surface coating comprising bioactive compound Download PDFInfo
- Publication number
- CA2503490A1 CA2503490A1 CA002503490A CA2503490A CA2503490A1 CA 2503490 A1 CA2503490 A1 CA 2503490A1 CA 002503490 A CA002503490 A CA 002503490A CA 2503490 A CA2503490 A CA 2503490A CA 2503490 A1 CA2503490 A1 CA 2503490A1
- Authority
- CA
- Canada
- Prior art keywords
- medical device
- peo
- factor
- protein
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000576 coating method Methods 0.000 title claims abstract 7
- 150000001875 compounds Chemical class 0.000 title claims 12
- 239000011248 coating agent Substances 0.000 title claims 4
- 230000000975 bioactive effect Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 claims abstract 17
- 108090000623 proteins and genes Proteins 0.000 claims abstract 17
- 230000001225 therapeutic effect Effects 0.000 claims abstract 13
- 230000024203 complement activation Effects 0.000 claims abstract 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 27
- 239000004094 surface-active agent Substances 0.000 claims 17
- 102000016550 Complement Factor H Human genes 0.000 claims 15
- 108010053085 Complement Factor H Proteins 0.000 claims 15
- 238000000034 method Methods 0.000 claims 15
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 claims 12
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims 12
- 239000004926 polymethyl methacrylate Substances 0.000 claims 12
- 229920001451 polypropylene glycol Polymers 0.000 claims 12
- 239000008280 blood Substances 0.000 claims 9
- 210000004369 blood Anatomy 0.000 claims 9
- 229920001577 copolymer Polymers 0.000 claims 8
- 230000002209 hydrophobic effect Effects 0.000 claims 8
- 108010009575 CD55 Antigens Proteins 0.000 claims 6
- 102000050019 Membrane Cofactor Human genes 0.000 claims 6
- 101710146216 Membrane cofactor protein Proteins 0.000 claims 6
- 239000005062 Polybutadiene Substances 0.000 claims 6
- 229920001400 block copolymer Polymers 0.000 claims 6
- -1 poly(N-acetylethyleneimine) Polymers 0.000 claims 6
- 229920002857 polybutadiene Polymers 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 6
- 229920002635 polyurethane Polymers 0.000 claims 6
- 239000004814 polyurethane Substances 0.000 claims 6
- 150000003462 sulfoxides Chemical class 0.000 claims 6
- 102100035324 Complement factor H-related protein 4 Human genes 0.000 claims 5
- 101000878133 Homo sapiens Complement factor H-related protein 4 Proteins 0.000 claims 5
- 102100035321 Complement factor H-related protein 3 Human genes 0.000 claims 4
- 101000878136 Homo sapiens Complement factor H-related protein 3 Proteins 0.000 claims 4
- RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 claims 3
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 claims 3
- 101710159767 C4b-binding protein alpha chain Proteins 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 108010033276 Peptide Fragments Proteins 0.000 claims 3
- 102000007079 Peptide Fragments Human genes 0.000 claims 3
- 101900335902 Vaccinia virus Complement control protein C3 Proteins 0.000 claims 3
- 241000700647 Variola virus Species 0.000 claims 3
- 102000023732 binding proteins Human genes 0.000 claims 3
- 108091008324 binding proteins Proteins 0.000 claims 3
- 150000001720 carbohydrates Chemical class 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 102000006834 complement receptors Human genes 0.000 claims 3
- 108010047295 complement receptors Proteins 0.000 claims 3
- 108010027437 compstatin Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims 2
- 238000001631 haemodialysis Methods 0.000 claims 2
- 210000003709 heart valve Anatomy 0.000 claims 2
- 230000000322 hemodialysis Effects 0.000 claims 2
- 238000002615 hemofiltration Methods 0.000 claims 2
- 230000001951 hemoperfusion Effects 0.000 claims 2
- 238000002616 plasmapheresis Methods 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- 238000000108 ultra-filtration Methods 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0017—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using a surface active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
Abstract
Coatings comprising protein resistant components and therapeutic components on medical devices are disclosed. The coatings act to down-regulate complement activation. Medical devices can be coated with these coatings to prevent side effects and improve patency.
Claims (39)
1. A medical device comprising:
a structure adapted for introduction into a patient or contact with blood or tissue of a patient, wherein the structure comprises a surface;
a layer of surfactant adsorbed on the surface of the medical device, wherein the surfactant on the surface of the medical device is substantially non-activating or deactivating to the complement cascade as compared to the non-coated surface of the medical device.
a structure adapted for introduction into a patient or contact with blood or tissue of a patient, wherein the structure comprises a surface;
a layer of surfactant adsorbed on the surface of the medical device, wherein the surfactant on the surface of the medical device is substantially non-activating or deactivating to the complement cascade as compared to the non-coated surface of the medical device.
2. The medical device of Claim 1, wherein the medical device is selected from the group consisting of balloon catheters, A/V shunts, vascular grafts, stems, pacemaker leads, pacemakers, heart valves, catheters, and guide wires.
3. The medical device of Claim 1, wherein the medical device is selected from the group consisting of cardiopulmonary bypass device, plasmapheresis device, plateletpheresis device, leukopheresis device, LDL removal device, hemodialysis device, hemofiltration filters, ultrafiltration device, hemoperfusion device, blood oxygenator, blood pump, blood sensor, and tubing used to carry blood which is then returned to the patient.
4. The medical device according to Claim 1, wherein the surfactant is selected from the group consisting of factor H, factor H like protein 1 (FHL-1), factor H
related proteins (FHR 3, FHR-4).
related proteins (FHR 3, FHR-4).
5. The medical device of Claim 1, wherein the surfactant comprises a block copolymer.
6. The medical device of Claim 1, wherein the surfactant comprises a block copolymer comprising hydrophobic regions and hydrophilic regions.
7. The medical device of Claim 1, wherein the surfactant comprises a PLURONICS block copolymer.
8. The medical device of Claim 1, wherein the surfactant comprises a therapeutic entity attached thereto.
9. The medical device of Claim 8, wherein the surfactant comprises a compound with the formula:
THERAPEUTIC ENTITY ~ COPOLYMER
wherein the copolymer comprises one or more hydrophilic domains and at least one hydrophobic domain.
THERAPEUTIC ENTITY ~ COPOLYMER
wherein the copolymer comprises one or more hydrophilic domains and at least one hydrophobic domain.
10. The medical device of Claim 9, wherein the therapeutic entity is a protein, protein fragment, peptide, oligonucleotide, carbohydrate, proteoglycan, antibody or drug.
11. The medical device of Claim 9, wherein the therapeutic entity is a regulator of complement activation or an active domain thereof.
12. The medical device of Claim 9, wherein the regulator of complement activation is selected from the group consisting of factor H, factor H like protein 1 (FHL-1), factor H related proteins (FHR-3, FHR-4), C4 binding protein (C4bp), complement receptor 1 (CR1), compstatin, decay-accelerating factor (DAF), membrane cofactor protein (MCP), vaccinia virus complement control protein (VCP) and small pox inhibitor of complement enzymes (SPICE).
13. The medical device of Claim 9, wherein the copolymer comprises polymer units selected from the group consisting of polyethylene oxide (PEO) and polypropylene oxide (PPO), PEO and polybutadiene, PEO and poly(N-acetylethyleneimine), PEO
and phenyl boronic acid, PEO and polyurethane, PEO and polymethylmethacrylate (PMMA), and PEO and polydimethyl sulfoxide.
and phenyl boronic acid, PEO and polyurethane, PEO and polymethylmethacrylate (PMMA), and PEO and polydimethyl sulfoxide.
14. The medical device of Claim 9, wherein the hydrophilic domain comprises polyethylene oxide.
15. The medical device of Claim 9, wherein the hydrophobic domain comprises a polymer unit selected from the group consisting of polypropylene oxide (PPO), polybutadiene, poly(N-acetylethyleneimine), phenyl boronic acid, polyurethane, polymethylmethacrylate (PMMA), and polydimethyl sulfoxide.
16. A method for coating a medical device with a surface coating comprising:
providing the medical device with a surface;
providing a surfactant;
adsorbing the surfactant on the surface of the medical device; wherein the surfactant on the surface of the medical device is substantially non-activating or deactivating to the complement cascade as compared to the non-coated surface of the medical device.
providing the medical device with a surface;
providing a surfactant;
adsorbing the surfactant on the surface of the medical device; wherein the surfactant on the surface of the medical device is substantially non-activating or deactivating to the complement cascade as compared to the non-coated surface of the medical device.
17. The method of Claim 16, wherein the medical device is selected from the group consisting of balloon catheters, A/V shunts, vascular grafts, stents, pacemaker leads, pacemakers, heart valves, catheters, and guide wires.
18. The method of Claim 16, wherein the medical device is selected from the group consisting of cardiopulmonary bypass device, plasmapheresis device, plateletpheresis device, leukopheresis device, LDL removal device, hemodialysis device, hemofiltration filters, ultrafiltration device, hemoperfusion device, blood oxygenator, blood pump, blood sensor, and tubing used to carry blood which is then returned to the patient.
19. The method according to Claim 16, wherein the surfactant is selected from the group consisting of factor H, factor H like protein 1 (FHL-1), factor H
related proteins (FHR-3, FHR-4).
related proteins (FHR-3, FHR-4).
20. The method of Claim 16, wherein the surfactant is adsorbed on the surface of the medical device with a block copolymer.
21. The method of Claim 16, wherein the surfactant is adsorbed on the surface of the medical device with a block copolymer comprising hydrophobic regions and hydrophilic regions.
22. The method of Claim 16, wherein the surfactant is adsorbed on the surface of the medical device with a PLURONICS block copolymer.
23. The method of Claim 16, wherein the surfactant comprises a therapeutic entity attached thereto.
24. The method of Claim 23, wherein the surfactant comprises a compound with the formula:
THERAPEUTIC ENTITY ~ COPOLYMER
wherein the copolymer comprises one or more hydrophilic domains and at least one hydrophobic domain.
THERAPEUTIC ENTITY ~ COPOLYMER
wherein the copolymer comprises one or more hydrophilic domains and at least one hydrophobic domain.
25. The method of Claim 24, wherein the therapeutic entity is a protein, protein fragment, peptide, oligonucleotide, carbohydrate, proteoglycan, antibody or drug.
26. The method of Claim 24, wherein the therapeutic entity is a regulator of complement activation or an active domain thereof.
27. The method of Claim 26, wherein the regulator of complement activation is selected from the group consisting of factor H, factor H like protein 1 (FHL-1), factor H related proteins (FHR-3, FHR-4), C4 binding protein (C4bp), complement receptor 1 (CR1), compstatin, decay-accelerating factor (DAF), membrane cofactor protein (MCP), vaccinia virus complement control protein (VCP) and small pox inhibitor of complement enzymes (SPICE).
28. The method of Claim 24, wherein the copolymer comprises polymer units selected from the group consisting of polyethylene oxide (PEO) and polypropylene oxide (PPO), PEO and polybutadiene, PEO and poly(N-acetylethyleneimine), PEO and phenyl boronic acid, PEO and polyurethane, PEO and polymethylmethacrylate (PMMA), and PEO and polydimethyl sulfoxide.
29. The method of Claim 24, wherein the hydrophilic domain comprises polyethylene oxide.
30. The method of Claim 24, wherein the hydrophobic domain comprises a polymer unit selected from the group consisting of polypropylene oxide (PPO), polybutadiene, poly(N-acetylethyleneimine), phenyl boronic acid, polyurethane, polymethylmethacrylate (PMMA), and polydimethyl sulfoxide.
31. A compound for coating a medical device with the formula:
wherein the copolymer comprises one or more hydrophilic domains and at least one hydrophobic domain.
wherein the copolymer comprises one or more hydrophilic domains and at least one hydrophobic domain.
32. The compound according to Claim 31, wherein the therapeutic entity is a protein, protein fragment, peptide, oligonucleotide, carbohydrate, proteoglycan, antibody or drug.
33. The compound according to Claim 31, wherein the therapeutic entity is a regulator of coagulation or an active domain thereof.
34. The compound according to Claim 33, wherein the therapeutic entity is an antibody.
35. The compound according to Claim 31, wherein the therapeutic entity is a regulator of complement activation or an active domain thereof.
36. The compound according to Claim 35, wherein the regulator of complement activation is selected from the group consisting of factor H, factor H like protein 1 (FHL-1), factor H related proteins (FHR-3, FHR-4), C4 binding protein (C4bp), complement receptor 1 (CR1), compstatin, decay-accelerating factor (DAF), membrane cofactor protein (MCP), vaccinia virus complement control protein (VCP) and small pox inhibitor of complement enzymes (SPICE).
37. The compound according to Claim 31, wherein the copolymer comprises polymer units selected from the group consisting of polyethylene oxide (PEO) and polypropylene oxide (PPO), PEO and polybutadiene, PEO and poly(N-acetylethyleneimine), PEO and phenyl boronic acid, PEO and polyurethane, PEO
and polymethylmethacrylate (PMMA), and PEO and polydimethyl sulfoxide.
and polymethylmethacrylate (PMMA), and PEO and polydimethyl sulfoxide.
38. The compound according to Claim 31, wherein the hydrophilic domain comprises polyethylene oxide.
39. The compound according to Claim 31, wherein the hydrophobic domain comprises a polymer unit selected from the group consisting of polypropylene oxide (PPO), polybutadiene, poly(N-acetylethyleneimine), phenyl boronic acid, polyurethane, polymethylmethacrylate (PMMA), and polydimethyl sulfoxide.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42039002P | 2002-10-21 | 2002-10-21 | |
| US60/420,390 | 2002-10-21 | ||
| PCT/US2003/033348 WO2004037310A2 (en) | 2002-10-21 | 2003-10-21 | Surface coating comprising bioactive compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2503490A1 true CA2503490A1 (en) | 2004-05-06 |
| CA2503490C CA2503490C (en) | 2012-04-03 |
Family
ID=32176561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2503490A Expired - Lifetime CA2503490C (en) | 2002-10-21 | 2003-10-21 | Medical device surface coating comprising bioactive compound |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7459169B2 (en) |
| EP (1) | EP1553993B1 (en) |
| JP (1) | JP5030383B2 (en) |
| AU (1) | AU2003284304B8 (en) |
| CA (1) | CA2503490C (en) |
| WO (1) | WO2004037310A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7858108B2 (en) | 2003-10-21 | 2010-12-28 | Richard Nagler | Elutable surface coating |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110165244A1 (en) * | 2003-10-21 | 2011-07-07 | Allvivo Vascular, Inc. | Bioresponsive polymer formulations for delivery of bioactive agents |
| US8048437B2 (en) | 2004-04-21 | 2011-11-01 | Richard Nagler | Medical device with surface coating comprising bioactive compound |
| US20060015057A1 (en) * | 2004-07-15 | 2006-01-19 | Ho Chih-Hu | Coating for arterial-venous blood tubing set for hemodialysis system |
| EP1781264B1 (en) | 2004-08-04 | 2013-07-24 | Evonik Corporation | Methods for manufacturing delivery devices and devices thereof |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| EP2662089A3 (en) * | 2005-10-08 | 2014-02-19 | Potentia Pharmaceuticals, Inc. | Compstatin and analogs thereof for eye disorders |
| ES2409759T3 (en) | 2007-01-21 | 2013-06-27 | Hemoteq Ag | Medical product for the treatment of stenosis of the channels of the body and for the prevention of threatening stenosis |
| US8263104B2 (en) * | 2007-06-08 | 2012-09-11 | Northwestern University | Polymer nanofilm coatings |
| US9192697B2 (en) | 2007-07-03 | 2015-11-24 | Hemoteq Ag | Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis |
| US8178617B2 (en) * | 2007-07-16 | 2012-05-15 | Allvivo Vascular, Inc. | Antimicrobial constructs |
| MX2010002351A (en) * | 2007-08-31 | 2010-05-27 | Univ Michigan | Selective cytopheresis devices and related methods thereof. |
| EP2222281B1 (en) | 2007-12-20 | 2018-12-05 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
| DE102008027133A1 (en) * | 2008-05-30 | 2009-12-03 | Ls Medcap Gmbh | Fully synthetic albumin analog |
| WO2009152167A2 (en) * | 2008-06-09 | 2009-12-17 | Northwestern University | Delivery of therapeutics |
| US10799593B2 (en) | 2008-06-09 | 2020-10-13 | Northwestern University | Nanodiamond particle complexes |
| US8226603B2 (en) | 2008-09-25 | 2012-07-24 | Abbott Cardiovascular Systems Inc. | Expandable member having a covering formed of a fibrous matrix for intraluminal drug delivery |
| US8049061B2 (en) | 2008-09-25 | 2011-11-01 | Abbott Cardiovascular Systems, Inc. | Expandable member formed of a fibrous matrix having hydrogel polymer for intraluminal drug delivery |
| US8500687B2 (en) | 2008-09-25 | 2013-08-06 | Abbott Cardiovascular Systems Inc. | Stent delivery system having a fibrous matrix covering with improved stent retention |
| US8076529B2 (en) | 2008-09-26 | 2011-12-13 | Abbott Cardiovascular Systems, Inc. | Expandable member formed of a fibrous matrix for intraluminal drug delivery |
| WO2010077646A2 (en) * | 2008-12-30 | 2010-07-08 | Bausch & Lomb Incorporated | Method of applying renewable polymeric lens coating |
| US8454689B2 (en) * | 2008-12-30 | 2013-06-04 | Bausch & Lomb Incorporated | Brush copolymers |
| EP2442839B1 (en) * | 2009-04-09 | 2017-10-04 | The University of Queensland | Block copolymer blends |
| EP2451496B1 (en) | 2009-07-10 | 2015-07-22 | Boston Scientific Scimed, Inc. | Use of nanocrystals for a drug delivery balloon |
| EP2962707B1 (en) | 2009-07-17 | 2019-07-24 | Boston Scientific Scimed, Inc. | Drug delivery balloons with improved crystal size and density |
| US20110056083A1 (en) * | 2009-09-08 | 2011-03-10 | Tsan-Ching Wang | Degradable string for string trimmer |
| WO2011163394A2 (en) | 2010-06-22 | 2011-12-29 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| EP2611476B1 (en) | 2010-09-02 | 2016-08-10 | Boston Scientific Scimed, Inc. | Coating process for drug delivery balloons using heat-induced rewrap memory |
| JP2014500735A (en) | 2010-10-15 | 2014-01-16 | サイトフェリックス インコーポレイテッド | Cytopheresis cartridge and its use |
| US8669360B2 (en) | 2011-08-05 | 2014-03-11 | Boston Scientific Scimed, Inc. | Methods of converting amorphous drug substance into crystalline form |
| US9056152B2 (en) | 2011-08-25 | 2015-06-16 | Boston Scientific Scimed, Inc. | Medical device with crystalline drug coating |
| CA2852220A1 (en) | 2011-10-14 | 2013-07-18 | Cytopherx, Inc. | Cartridge and method for increasing myocardial function |
| PL2920201T3 (en) | 2012-11-15 | 2020-10-05 | Apellis Pharmaceuticals, Inc. | Long-acting compstatin analogs and related compositions and methods |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| CH708835A1 (en) * | 2013-11-14 | 2015-05-15 | Qvanteq Ag | Implant with improved surface properties. |
| EP3359555B1 (en) | 2015-10-07 | 2023-12-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
| WO2018187813A1 (en) | 2017-04-07 | 2018-10-11 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| WO2019073992A1 (en) * | 2017-10-11 | 2019-04-18 | 国立大学法人京都大学 | Antibody-modified filter |
| DE102019102597A1 (en) * | 2019-02-01 | 2020-08-06 | DC Diagnostics Concept UG (haftungsbeschränkt) | Container for storing a body fluid |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2433883C2 (en) * | 1973-07-20 | 1986-03-27 | Research Corp., New York, N.Y. | Use of physiologically active polypeptides |
| SE430062B (en) | 1977-03-04 | 1983-10-17 | Pharmacia Fine Chemicals Ab | COUPLING OR TIOLATION REAGENTS |
| SE8102194L (en) | 1981-04-06 | 1982-10-07 | Pharmacia Ab | THERAPEUTIC ACTIVE ORGANIC ASSOCIATION AND PHARMACEUTICAL PREPARATION INCLUDING THIS |
| JPS6031762A (en) * | 1983-08-03 | 1985-02-18 | テルモ株式会社 | Artificial blood vessel |
| US4865870A (en) * | 1988-07-07 | 1989-09-12 | Becton, Dickinson And Company | Method for rendering a substrate surface antithrombogenic |
| US4975468A (en) * | 1989-04-03 | 1990-12-04 | Affinity Biotech, Inc. | Fluorinated microemulsion as oxygen carrier |
| US5576016A (en) * | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
| WO1997035886A1 (en) * | 1996-03-22 | 1997-10-02 | Imutran Limited | Surfaces which prevent or reduce complement activation |
| US5869539A (en) * | 1996-04-17 | 1999-02-09 | Board Of Regents, The University Of Texas System | Emulsions of perfluoro compounds as solvents for nitric oxide (NO) |
| US5877263A (en) * | 1996-11-25 | 1999-03-02 | Meadox Medicals, Inc. | Process for preparing polymer coatings grafted with polyethylene oxide chains containing covalently bonded bio-active agents |
| US6066602A (en) * | 1997-08-07 | 2000-05-23 | Becton Dickinson And Company | Waterborne non-silicone lubricant comprising phospholipid and polyether |
| IT1315220B1 (en) * | 1999-12-13 | 2003-02-03 | Ipm Ind Plastica Monregalese | MULTI-LAYER PLASTIC LEAF CANVAS FOR PACCIAMATURE AND / OR AS BARRIER CONTAINING TREATMENT SUBSTANCES IN |
| JP2003520645A (en) * | 2000-01-25 | 2003-07-08 | エドワーズ ライフサイエンシーズ コーポレイション | Bioactive coating prevents tissue overgrowth on artificial heart valves |
| ATE374785T1 (en) * | 2000-03-02 | 2007-10-15 | Mitsubishi Pharma Corp | GPIB BONDED CONSTRUCT AND USES THEREOF |
| ATE430194T1 (en) * | 2001-02-02 | 2009-05-15 | Allvivo Inc | END-GROUP-ACTIVATED POLYMERS WITH OLIGONUCLEOTIDE LIGANDS |
-
2003
- 2003-10-21 WO PCT/US2003/033348 patent/WO2004037310A2/en active Application Filing
- 2003-10-21 JP JP2004546970A patent/JP5030383B2/en not_active Expired - Fee Related
- 2003-10-21 EP EP03776485.9A patent/EP1553993B1/en not_active Expired - Lifetime
- 2003-10-21 AU AU2003284304A patent/AU2003284304B8/en not_active Ceased
- 2003-10-21 US US10/689,869 patent/US7459169B2/en not_active Expired - Fee Related
- 2003-10-21 CA CA2503490A patent/CA2503490C/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7858108B2 (en) | 2003-10-21 | 2010-12-28 | Richard Nagler | Elutable surface coating |
Also Published As
| Publication number | Publication date |
|---|---|
| US7459169B2 (en) | 2008-12-02 |
| WO2004037310A3 (en) | 2004-07-01 |
| JP2006510396A (en) | 2006-03-30 |
| WO2004037310A2 (en) | 2004-05-06 |
| AU2003284304B2 (en) | 2009-07-23 |
| AU2003284304A1 (en) | 2004-05-13 |
| JP5030383B2 (en) | 2012-09-19 |
| US20040142011A1 (en) | 2004-07-22 |
| EP1553993A2 (en) | 2005-07-20 |
| AU2003284304B8 (en) | 2009-08-06 |
| EP1553993B1 (en) | 2016-03-30 |
| CA2503490C (en) | 2012-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2503490A1 (en) | Medical device surface coating comprising bioactive compound | |
| JP2006510396A5 (en) | ||
| JP2806510B2 (en) | Artificial organ membrane or medical device | |
| US5447724A (en) | Medical device polymer | |
| EP0941740A2 (en) | Attachment of biomolecules to surfaces of medical devices | |
| KR100511030B1 (en) | Blood compatible metallic materials and preparation thereof | |
| EP2518100B1 (en) | Hydrophilic polymer compound having anticoagulation effect | |
| US8114465B2 (en) | Process for preparing a substrate coated with a biomolecule | |
| Roberts et al. | Toward an artificial endothelium: Development of blood-compatible surfaces for extracorporeal life support | |
| EP1207814A1 (en) | Method for producing improved medical devices and devices so produced | |
| AU2001247579A1 (en) | Matrices containing nitric oxide donors and reducing agents and their use | |
| EP2724733A1 (en) | Hydrophobic polymer compound having anticoagulant effect | |
| WO2012176861A1 (en) | Medical supply | |
| CN1976648A (en) | Hemodialysis tube treated with medicament on surface thereof for connecting artery to vein | |
| US20020198590A1 (en) | Method for producing medical devices and devices so produced | |
| JPH07178166A (en) | Artificial organ | |
| Bambauer et al. | Long‐term catheters for apheresis and dialysis with surface treatment with infection resistance and low thrombogenicity | |
| JP2004357826A (en) | Medical instrument | |
| Ukita et al. | Extracorporeal artificial organs and therapeutic devices | |
| Lewis et al. | Blending in with the body | |
| van den Goor et al. | Adhesion of thrombotic components to the surface of a clinically used oxygenator is not affected by Trillium coating | |
| Urban et al. | Insulin binding to the cardiopulmonary bypass biomaterials | |
| Südkamp et al. | Cardiopulmonary bypass copolymer surface modification reduces neither blood loss nor transfusions in coronary artery surgery | |
| Valiathan | A new look at prosthetic materials. | |
| JPH07204263A (en) | Anti-thrombus medical treatment material and artificial blood vessel, artificial lung, dialysis membrane, dialysis circuit and intravascular |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20231023 |